Anaplastic Large Cell Lymphoma: Crizotinib Approved for Younger Patients

Crizotinib (Xalkori®, Pfizer) is now FDA approved for the treatment of pediatric patients age one year and older and young adult patients with relapsed/refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL). The approval was based on Study ADVL0912 (NCT00939770), a single-arm phase 1/2 trial. "Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as ALCL, inflammatory myofibroblastic tumors, non-small cell lung cancer (NSCLC), and neurob...

Anlotinib Shows Benefit in Refractory Metastatic Colorectal Cancer

Standard treatment for metastatic colorectal cancer (mCRC) typically involves antiangiogenic therapies, which block angiogenesis, the formation of new blood vessels, thereby starving cancer cells. Anlotinib, a multitarget tyrosine kinase inhibitor, works by targeting VEGFR1-3, which hinders tumor metastasis and growth. In study results to be presented this weekend at the 2021 Gastrointestinal Cancers Symposium, anlotinib demonstrated efficacy in patients with previously treated mCRC. ALTER0703, ...

Perioperative TAS-118 Plus Oxaliplatin Feasible in Gastric Cancer

In patients with locally advanced gastric cancer, perioperative chemotherapy consisting of TAS-118 (S-1 and leucovorin) plus oxaliplatin shows promise with a tolerable safety profile, according to safety and efficacy results of the APOLLO-11 feasibility study to be presented this week at the 2021 Gastrointestinal Cancers Symposium. While preoperative TAS-118 plus oxaliplatin followed by D2 gastrectomy has been shown to be feasible for patients with gastric cancer, the efficacy of this regimen in...

Locally Advanced Pancreatic Cancer: Reducing Lymphopenia to Improve Outcomes

Lymphopenia—a condition where lymphocyte levels in blood are below normal—is frequently caused by chemoradiation (CRT). Since lymphopenia is associated with worse survival outcomes in patients with cancer, there is a huge need to decrease this condition. Researchers found that in patients with nonmetastatic, unresectable pancreatic ductal adenocarcinoma (PDAC) who have been treated with neoadjuvant 5-fluorouracil (5FU)/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) and CRT, severe lymphopenia ca...

Darolutamide for Castration-Resistant Prostate Cancer: FDA Updates Prescribing Info

The FDA has added new overall survival and other secondary outcome data to the prescribing information for darolutamide (Nubeqa®, Bayer), an androgen receptor inhibitor which was approved for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC) in 2019. The updates were based on the final analysis of the phase 3 ARAMIS trial (NCT02200614), led by first author Karim Fizazi, MD, Head of the Department of Cancer Medicine at the Institut Gustave Roussy in Villejuif, France. The...

Copyright © 2021 Oncology Data Advisor. All rights reserved.